April 2026
April 2026
Pharma.AI Spring Kickoff, AIM Congress keynote, and Peakspan debuts
A globally distributed month. Alex spoke at AIM Congress 2026 in Dubai, delivered a Yale Venture Club masterclass, keynoted Microsoft AI Tour Shanghai, addressed CNBC Converge Live in Singapore, and joined the Breakthrough Technology Dialogue. Insilico's Pharma.AI Spring Kickoff — profiled by Science Magazine — showcased new target-discovery programs, including a breakthrough in selective PKMYT1 inhibitors and the nomination of ISM6200 as a best-in-class NR3C1 candidate. Media coverage was expansive: STAT ran an interview on how best to use AI in drug development, Fortune covered the Hong Kong capital-markets renaissance with Insilico as a marquee name, and The Economist, Fortune Herald, and a Forbes column ("AIRA_2: Breaking Bottlenecks In AI Research Agents") all weighed in. The month's signature essay was the Forever.ai piece "Peakspan: The True North of Longevity and Why We Must Aim Beyond Healthspan" — an intellectual capstone to the new concept Alex and Dominika Wilczok formalized in their arXiv preprint. Notable in-person visits included Eli Lilly's CSO at LGL Shanghai and the UAE Ministry of Investment Undersecretary touring the Insilico automation lab.
AIM Congress 2026 keynote (Dubai)Microsoft AI Tour ShanghaiCNBC Converge Live (Singapore)Peakspan essay launched on Forever.aiPKMYT1 & NR3C1 program milestonesSTAT interview on AI in drug development
March 2026
March 2026
The $2.75B Lilly deal lands — a defining moment
The month Insilico's long partnership with Eli Lilly turned into the largest AI-drug-discovery collaboration on record. On March 29, Lilly extended its relationship with Insilico in a deal worth up to $2.75 billion, with $115M upfront. The story dominated the global press in a single day: Bloomberg, Reuters, Fierce Biotech, Endpoints, STAT News, and the Financial Times all ran coverage, and Insilico shares surged. Two days later, the New York Times covered Lilly's separate $6.3B narcolepsy-developer acquisition, contextualizing the company's accelerating AI-driven strategy. Nature ran a "Voices of biotech leaders" feature that included Alex. On the conference circuit this was an extraordinarily packed month: PMWC 2026 in Silicon Valley, Lab of the Future Boston, Morgan Stanley's China Summit, Milken Institute's Global Investors' Symposium in Hong Kong, LSX World Congress in Lisbon, the a2 National Symposium in Washington DC, and multiple speaking engagements in Shanghai with AstraZeneca, Bloomberg, and Bayer. By any measure, a landmark month.
$2.75B Eli Lilly deal ($115M upfront)PMWC 2026 Silicon ValleyLSX World Congress LisbonMilken Global Investors Symposium Hong KongMorgan Stanley China SummitNature: Voices of biotech leaders
February 2026
February 2026
Don't Die SF keynote, UC Berkeley, Web Summit Qatar
A month anchored by high-profile keynotes. Alex delivered the longevity × AI keynote and fireside Q&A at Bryan Johnson's Don't Die SF, spoke at the UC Berkeley AI Summit, and presented at Web Summit Qatar in Doha. He also headlined UBS's Longevity Series in Australia and Handelsblatt's Annual Pharma Conference. Media coverage leaned philosophical: Science News explored whether we've entered a new age of AI-enabled scientific discovery, TechCrunch profiled how AI is helping solve the labor bottleneck in rare-disease treatment, and Alex's own Forbes column argued that "The Most Impactful AI Is The Technology You Will Never Chat With." Boehringer Ingelheim's global team visited the Insilico automation lab in Shanghai, and Canaccord Genuity hosted its fibrotic-lung-disease symposium featuring Insilico's rentosertib program.
Don't Die SF keynoteUC Berkeley AI SummitWeb Summit QatarForbes: Most impactful AI you'll never chat withBI global team lab visit Shanghai
January 2026
January 2026
Post-IPO dealmaking blitz & the Nature Reviews Drug Discovery cover
The first post-IPO month opened with a torrent of deals. Servier licensed Insilico's AI platform for early oncology R&D (STAT, Endpoints); a Fosun Pharma-funded biotech licensed Insilico's NLRP3 inhibitor for Parkinson's; and Qilu Pharmaceutical signed a $120M cardiometabolic collaboration covered by Reuters and Endpoints. Fortune ran a feature on Insilico's launch of an MMA 'AI gym' to train models like GPT and Qwen for science; Microsoft's blog detailed AI-native drug discovery with Insilico's Nach01 model on Microsoft Discovery. On the science side, Alex's team published prolifically: the landmark target-identification review in Nature Reviews Drug Discovery, "From Prompt to Drug: Toward Pharmaceutical Superintelligence" in ACS Central Science, "The End of Aging Clocks" bioRxiv preprint, and "Past, present and future perspectives on the science of aging" in Nature Aging. Alex also attended J.P. Morgan 2026 and spoke at the JPM AIDD event. Three Forever.ai essays shipped — including a 2025 year-in-review and the provocative "Woke Longevity" piece.
Servier oncology dealQilu Pharmaceutical $120M cardiometabolic dealFosun/Hygtia NLRP3 licensingNature Reviews Drug Discovery target-ID reviewACS Central Science: Pharmaceutical SuperintelligenceMMAI Gym launch (Fortune)JPM 2026 + AIDD event
December 2025
December 2025
The IPO — Insilico debuts on HKEX as 3696.HK
The milestone month. On December 30, Insilico Medicine priced its Hong Kong IPO — a debut covered simultaneously by CNBC, Reuters, Bloomberg, Forbes, and Yahoo Finance. Forbes declared "AI Drug Discovery Unicorn Insilico Medicine Jumps In Hong Kong Trading Debut"; Bloomberg noted the surge "amid AI drugmaking optimism"; Reuters framed it as the cap on a bumper year of Chinese listings. CNBC interviewed Alex on how IPO funds will scale AI drug discovery; Yahoo Finance ran a piece on China's centrality to Insilico's plan to build biotech's AI 'Einstein.' Endpoints had previewed the raise (~$260M with Lilly's anchor support) earlier in the month. Alongside the listing, Alex spoke at the ASCPT rare-diseases webinar and at Proxima Ventures' 8th-anniversary celebration in Hangzhou. The Forever.ai column, "Longevity Couture," took an unexpected detour into fashion.
🎉 HKEX IPO on December 30 (3696.HK)Bloomberg, Reuters, CNBC, Forbes IPO coverage~$260M raise with Lilly anchor supportASCPT rare-diseases webinarForever.ai: Longevity Couture
November 2025
November 2025
Lilly adds a $100M+ research pact; BIO-Europe Vienna
A second Lilly deal — worth over $100M — landed on Nov 10 (Fierce Biotech), foreshadowing the much larger March 2026 extension. Fortune ran a major feature arguing GLP-1s could become "the first true longevity drug," positioning Alex's team's thesis in the mainstream. Nature published "Drugmakers share data to feed voracious foundation models," quoting Alex on the industry shift. Travel was intense: BIO-Europe Vienna, Bosphorus Summit in Istanbul, Novartis China Partnering Forum, PRISME Technical Meeting in San Francisco, the Fortune Innovation Forum in Malaysia, Morgan Stanley's Asia-Pacific Summit in Singapore, the Korean Academy of Science and Technology Forum, "Think Business, Think Hong Kong" in Milan, and FII PRIORITY Asia in Tokyo. Alex also signed the Lilly AMR collaboration in Shanghai and spoke at the BARDA AI Community of Practice and a CIIE event on AI-reshaped global biopharma. Forever.ai ran a piece on NLRP3 as the "Swiss Army Knife" longevity target.
Lilly $100M+ research pactBIO-Europe ViennaFortune Innovation Forum MalaysiaMorgan Stanley Asia-Pacific SummitFII PRIORITY TokyoFortune: GLP-1s as first true longevity drug
October 2025
October 2025
FII Riyadh, Fortune Global Forum, and a Harvard Business School lecture
A Boston-and-Gulf marathon. Alex guest-lectured at Harvard Business School, spoke at the Harvard Medical School Biomarkers of Aging Conference, keynoted STAT Summit-adjacent events, and delivered a presentation for Regeneron Pharmaceuticals in NY. He then flew to Riyadh for the Fortune Global Forum and the ninth Future Investment Initiative (both speaking slots), finishing at the Galien Forum USA and Galien Patient Summit in New York. Other stops: Fierce Biotech Week Boston, IBIWS Shanghai, WHYSUMMIT Boston, BIOCentury China Summit, and BIOHK in Hong Kong. The Forever.ai column explored "on/off switch drugs" as an Ozempic-class solution for insomnia.
Harvard Business School guest lectureHarvard Biomarkers of Aging ConferenceFortune Global Forum RiyadhFII 9th Edition RiyadhGalien Forum USABIOHK Hong Kong
September 2025
September 2025
Financial Times profile and the Observer's AI-100 list
A month of deep-read profiles. The Financial Times ran two major pieces: "Inside the billion-dollar quest to live beyond 100" and a critical feature, "Why is AI struggling to discover new drugs?" The Observer profiled Alex's vision for "Pharma Superintelligence" and named him to its 100 Leaders Shaping the Future of Artificial Intelligence. Alex led a five-day Longevity Platinum Trip in Boston, attended Morgan Stanley's 23rd Annual Global Healthcare Conference in New York, spoke at BIOHK preview events in Hong Kong, and addressed the British Association for Lung Research. Two Forever.ai essays shipped: "GLP-1s: The world's first longevity drug?" and a strategic piece, "AI as a Stakeholder: What Every Pharma CEO Should Know About Communicating with AI."
FT: Inside the billion-dollar quest to live beyond 100Observer: Pharma Superintelligence profileObserver 100 AI LeadersLongevity Platinum Trip BostonForever.ai: GLP-1s as world's first longevity drug
August 2025
August 2025
ARDD Copenhagen and a new Shanghai lab
Summer was anchored by the 12th Aging Research and Drug Discovery (ARDD) meeting in Copenhagen, where Alex delivered his traditional August lineup of talks. He opened a new Shanghai lab, delivered a DDN webinar on AI and machine learning in multiomics, and was featured in TechCrunch's list of 33 US AI startups that had raised $100M+ in 2025. Forever.ai ran two sharp essays: "Beyond GLP-1: Is NLRP3 the Next Trillion Dollar Target?" and "Decoding Longevity: How AI is Ranking the Top Pharma Players" — both seeded debate heading into the autumn conference season.
ARDD 2025 CopenhagenNew Shanghai lab openingTechCrunch $100M+ AI startups featureForever.ai: NLRP3 as next trillion-dollar target
July 2025
July 2025
WIRED asks: Where are all the AI drugs?
A reflective month dominated by the WIRED story "Where Are All the AI Drugs?" — a challenge Alex answered with data. Fortune ran "AI is already touching nearly every corner of the medical field." Travel included the AI for Good Global Summit in Geneva, a US Roadshow, and an HKIC delegation trip through Brunei and Malaysia. Forever.ai published "Hacking Humanity: How technology can save your health and your life."
WIRED: Where Are All the AI Drugs?AI for Good Global Summit GenevaHKIC Southeast Asia delegationForever.ai: Hacking Humanity
June 2025
June 2025
BIO 2025 Boston, Founders Forum London, and CBA-CHINA Suzhou
A conference-heavy month spanning three continents. Alex spoke at BIO 2025 Boston, TD Cowen's "Tools/Dx Revolution" in Dana Point, the Boao Forum for Asia's International Science, Technology & Innovation Forum in Hong Kong, the Founders Forum in London, and the CBA-CHINA Annual Conference in Suzhou. Bloomberg interviewed Insilico's Alex Aliper on business outlook. The month's Forever.ai column reviewed Eric Topol's "Super Agers."
BIO 2025 BostonTD Cowen Tools/Dx RevolutionBoao Forum Hong KongFounders Forum LondonCBA-CHINA Suzhou
May 2025
May 2025
Microsoft CEO Summit and 'Toward Pharmaceutical Superintelligence'
Alex attended the Microsoft CEO Summit in Washington, spoke at ATS 2025 in San Francisco, and led the Invest UAE Roadshow on advanced manufacturing and life sciences in Guangzhou. Bloomberg ran back-to-back features: one on quantum computing as the future of drug development, another on "AI-Generated Drugs to Reach Market by 2030." TIME included Alex's field in its Top 10 AI-Led Contributions to Society. Three major Forever.ai essays shipped: "Toward Pharmaceutical Superintelligence" (the conceptual manifesto), a provocative taurine-and-cancer piece, and an analysis of 23andMe's bankruptcy and human-genomic-data privacy.
Microsoft CEO SummitATS 2025 San FranciscoBloomberg: AI drugs by 2030TIME Top 10 AI contributionsForever.ai: Toward Pharmaceutical Superintelligence
April 2025
April 2025
Insilico becomes an AI-drug unicorn's gold standard
Fortune ran a definitive feature: "Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market," centering Insilico in the conversation. TechCrunch highlighted Insilico among 19 new tech unicorns of 2025, and Forbes explored "8 Startup Opportunities In Anti-Ageing." On the road: Abu Dhabi Global Health Week, AACR Annual Meeting in Chicago, the Aramco-Chatterjee Group Executive Forum at Berkeley, and SABPA's 17th Annual Biomedical Forum. This is also when the flagship rentosertib Phase 2a Nature Medicine paper was being finalized for its summer publication.
Fortune: Multi-billion AI cancer-cure raceAACR Annual Meeting ChicagoAbu Dhabi Global Health WeekTechCrunch 2025 unicorn list
March 2025
March 2025
$110M Series E closes, SXSW, and HSBC Global Investment Summit
Insilico closed a $110M Series E — coverage everywhere: Bloomberg (noting a Hong Kong IPO on the horizon), Fierce Biotech ("new trials and robotic helping hands"), Endpoints (after stalling earlier IPO plans), and Forbes ("hits Unicorn status with 110 million"). CNBC contextualized the round within the DeepSeek-fueled China VC spigot. Alex spoke at SXSW in Austin, the HSBC Global Investment Summit in Hong Kong, Morgan Stanley's TMT Conference, HumanX in Las Vegas, Debiopharm's Digital Day, and ARDD China in Shanghai.
$110M Series E closeBloomberg: HK IPO on horizonSXSW Conference & FestivalsHSBC Global Investment SummitHumanX Las Vegas
February 2025
February 2025
Nature on powering up AI for drug discovery; World AI Cannes Festival
Nature ran "Four ways to power-up AI for drug discovery," a major methods-level article. Alex spoke at the Global Healthspan Summit in Riyadh, World AI Cannes Festival, the Global Business Summit in New Delhi, ME:25 in Abu Dhabi, Bank of America's 2025 Breakthrough Technology Dialogue Asia Pacific in Singapore, and HKTDC's Innovation and Technology Advisory Committee in Hong Kong. He also spent time at LEAP Riyadh. A quieter media month, but the Nature piece anchored the science-communication agenda for spring.
Nature: Four ways to power-up AI for drug discoveryGlobal Healthspan Summit RiyadhWorld AI Cannes FestivalBofA Breakthrough Tech Dialogue APACLEAP Riyadh
January 2025
January 2025
Menarini's second Insilico deal, BBC coverage, and 60 papers land
A year that opened with its own fireworks. On January 10, Menarini's Stemline signed a second exclusive global license with Insilico for an AI-discovered preclinical oncology asset — coverage ran from Fierce Biotech ($550M deal) to The Manila Times and Endpoints. The BBC ran "How AI uncovers new ways to tackle difficult diseases," The Economist declared "An AI revolution in drugmaking is under way," and The Guardian explored "Speedier drug trials and better films." Fortune covered AI for drug discovery's $5.6B Google spinoff moment. The January publication tranche was enormous — 60+ papers bylined that year surfaced through this window, including the Nature Biotechnology flagship on the TNIK inhibitor (Ren, Aliper, Chen, Zhao, Rao, Kuppe, Ozerov et al., 308 citations as of writing), the Nature Medicine Phase 2a rentosertib paper (105 citations), a Nature Biotechnology quantum-computing-enhanced KRAS paper (103 citations), and a Nature communications ENPP1-STING modulator. Alex spoke at the 2025 JPM Healthcare Conference, AUTONOMOUS, and the Academy of Health & Lifespan Research in Scottsdale.
Menarini $550M+ 2nd Insilico dealBBC: How AI uncovers new disease treatmentsNature Biotechnology: TNIK inhibitor (308 citations)Nature Medicine: Phase 2a rentosertibJPM Healthcare Conference 202560+ papers in 2025 publication tranche
December 2024
December 2024
Abu Dhabi Finance Week and a Bloomberg × Global X feature
A wind-down month with high-signal coverage. Bloomberg × Global X ran an Insilico feature on "expediting drug development." Fortune cited Alex's thinking in its Deloitte CEO survey piece on CEO optimism. Yahoo Finance reported on Insilico's generative-AI IBD drug. Alex spoke at Abu Dhabi Finance Week (ADFW) 2024 and Abu Dhabi Business Week (ADBW), lectured at Beiersdorf AG in Hamburg, attended the San Francisco CEOI dinner, and co-hosted the Second Workshop on New Frontiers of AI for Drug Discovery at a major ML venue in Vancouver. Science Daily profiled a tool Insilico developed to fast-track protein-interaction measurement.
Abu Dhabi Finance Week 2024Bloomberg × Global X featureNeurIPS workshop VancouverBeiersdorf AG scientific dialogue
November 2024
November 2024
ISM001-055 Phase 2a positive topline — and the Fortune 50 AI Innovators list
A breakthrough month. On November 13, Insilico announced positive topline Phase 2a results for ISM001-055 (rentosertib) in idiopathic pulmonary fibrosis — the first-ever Phase 2 readout for an end-to-end, AI-generated drug. TIME, Fierce Biotech, the Observer, Fortune, and Forbes ("Positive Clinical Trial Results For Generative AI-Designed Drug") all covered it. News Medical also reported on ISM5939 receiving IND clearance for cancer trials. Fortune named Insilico to its inaugural "50 AI Innovators" list. Fortune also ran a CEO feature on AI shaking up the workforce. Alex spoke at Fortune Global Forum NYC, the 2024 Global Healthy Longevity Conference in Shenzhen, Nature Portfolio's Drug Discovery Forum in Beijing, Boehringer Ingelheim's AI Summit in Connecticut, the 12th ChemIndix conference in Dhahran, and Morgan Stanley's Asia Pacific Summit in Singapore.
🎉 Phase 2a positive topline for rentosertib (first AI-generated drug)Fortune 50 AI InnovatorsISM5939 IND clearanceFortune Global Forum NYCMorgan Stanley APAC Summit SingaporeNature Portfolio Drug Discovery Forum Beijing
October 2024
October 2024
FII Riyadh, JLABS CEO Summit NY, and Frontiers Health Berlin
A travel-dense month. Alex spoke at the 8th Future Investment Initiative in Riyadh, the JLABS CEO Summit 2024 in New York, Frontiers Health 2024 in Berlin, GITEX Global × Expand North Star in Dubai, the Aramco Entrepreneurship Summit in Dhahran, and the 7th WLA Forum in Shanghai. CNN Arabia profiled his thinking on AI-driven drug development. He also led the NCATS In silico Drug Discovery Workshop and a BI symposium on data science and AI impact on drug discovery.
FII 8th Edition RiyadhJLABS CEO Summit 2024Frontiers Health BerlinGITEX Global DubaiAramco Entrepreneurship Summit
September 2024
September 2024
Insilico's Boston office opens; United Nations Science Summit
A significant infrastructure month. Insilico opened its Boston office on September 18. Alex lectured at Harvard Law on the same trip, spoke at The Atlantic Festival in Washington DC, Constellation's AI Forum in New York, the AWS Climate Tech & AI event, and the United Nations Science Summit on "Generative AI in Medicine." He also attended Don't Die Summit in San Francisco, Morgan Stanley's Global Healthcare Conference, Fortune CEOI Seattle, and helped kick off Boston Biotechnology Week. Fortune ran "Aging is the inflation of life" — a feature arguing longevity biotech companies need investor patience. Key publications this year began surfacing: the Precious2GPT multiomics transformer (npj Aging), Precious3GPT (bioRxiv), and "Validation of biomarkers of aging" (Nature Medicine, 302 citations).
Boston office launchHarvard Law lectureUN Science SummitAtlantic Festival DCFortune: Aging is the inflation of life
August 2024
August 2024
ARDD 2024 Copenhagen; Nature on AI dealmaking
The annual ARDD meeting anchored the month. Nature published a high-profile piece — "Generative AI platforms drive drug discovery dealmaking" — citing Insilico's momentum. The Gulf Observer News covered foreign biotech companies expanding in China with Insilico as a case study.
ARDD 2024 CopenhagenNature: Generative AI drives dealmaking
July 2024
July 2024
WAIC Shanghai and Fortune's 'We need a ChatGPT for longevity' interview
Alex delivered a suite of speaking engagements at the World AI Conference (WAIC) 2024 in Shanghai, the 2024 Luohan Academy Annual Digital Economy Conference, and the WAIC China-UAE AI Industrial Finance Cooperation Forum. He headlined the inaugural Fortune Brainstorm AI Singapore and the SCRI Clinical Trial Symposium. Fortune ran a provocative Alex-quoted piece — "Only an AI breakthrough can help humans live longer, argues drug developer: 'We need a ChatGPT...'" — while Yahoo Finance covered Brainstorm AI's "1,000-Year-Old Human" session. Fierce Biotech covered Insilico's launch of an AI assistant for drafting medical research papers.
WAIC 2024 Shanghai (3 sessions)Fortune Brainstorm AI Singapore (inaugural)Fortune: We need a ChatGPT for longevityInsilico medical research AI assistant launch
June 2024
June 2024
Longevity Summit Dublin and the London Tech Week circuit
A packed European and Asian calendar. Alex keynoted Longevity Summit Dublin 2024, attended London Tech Week and the Founders Longevity Forum in London, spoke at the WEF Annual Meeting of the New Champions in Dalian, and addressed the First CBA-CHINA Annual Conference in Suzhou. Other stops: the International Baltic Conference on Healthy Longevity, the Gordon Research Conference on Systems Aging, AFAR's AI Drug Discovery for Longevity webinar, and Microsoft's Pharma Executive AI Roundtable. Forbes ran "How Generative AI Is Accelerating Drug Discovery."
Longevity Summit Dublin 2024London Tech WeekWEF Dalian (Annual Meeting of New Champions)CBA-CHINA First Annual Conference
May 2024
May 2024
WEF Riyadh and a Science piece on quantum computing in chemistry
Alex attended the World Economic Forum Special Meeting in Saudi Arabia (a high-signal policy gathering), spoke at Abu Dhabi Global Healthcare Week, the J.P. Morgan Global China Summit in Shanghai, and IFCC WorldLab 2024 in Dubai. Science magazine featured him in its "Compound Interest" piece on practical quantum-computing uses in chemistry. The Financial Times ran "AI-powered drug discovery demands investor patience," and South China Morning Post covered Hong Kong's innovation-hub push. CNBC reported on generative AI accelerating human-like robot development. Forbes ran "Go Forth, And Fight Aging" plus a Majlis/UAE column on peace, tolerance, and AI.
WEF Special Meeting RiyadhAbu Dhabi Global Healthcare WeekScience: Quantum in chemistry featureFT: AI drug discovery demands patienceForbes: Go Forth, And Fight Aging
April 2024
April 2024
The Economist asks: Can biotech upstage Lilly and Novo?
Alex and Insilico were everywhere. The Economist ran "Can biotech startups upstage Eli Lilly and Novo Nordisk?", Fortune reported on "$1B launch—and a lot of hope" for AI drug discovery, the Irish Times ran a feature on AI accelerating drug discovery, and Nature Aging published "Drug discovery by AI trained on aging biology." The Spanish edition of MIT Tech Review led with an Insilico milestone story. Alex spoke at AACR Annual Meeting in San Diego (+ partnering event), the World Future Energy Summit in Abu Dhabi, the Nature Conference: Advancing Health with AI in Wenzhou, and the WEF Special Meeting in Saudi Arabia (prep week). Forbes columns included "Meta's Release Of Llama 3 Changes Everything" and "5 Tips To Enhance Your Research Paper's Visibility And Altmetric Score."
The Economist: Biotech vs. Lilly/NovoNature Aging: AI trained on aging biologyAACR 2024 San DiegoNature Conference Wenzhou: Advancing Health with AIForbes: Meta Llama 3 Changes Everything
March 2024
March 2024
Nature Biotechnology TNIK paper: the turning point in AI drug discovery
The month the field turned a corner. The Economist ran "Artificial Intelligence is taking over drug development." MIT Tech Review followed with "A Wave of Drugs Dreamed Up By AI Is On Its Way." Nature published "AI serves up target and inhibitor for lung fibrosis" — summarizing the landmark TNIK/rentosertib paper. Fast Company named Insilico to its Most Innovative Companies in Biotech list and profiled how it's using generative AI for cutting-edge treatments. Fortune, Fierce Biotech, and VentureBeat all covered the TNIK paper and its implications. Alex keynoted the 44th JPM Health Care Conference prep, LEAP 2024 Riyadh, the Milan Longevity Summit, and the Fortune Innovation Forum 2024 in Hong Kong. A definitive month for the field's credibility.
🎉 Nature Biotechnology: TNIK paper (AI-discovered drug to clinic)MIT Tech Review cover: Wave of AI drugsFast Company Most Innovative Biotech (Insilico)The Economist: AI takes over drug developmentFortune Innovation Forum 2024 HKLEAP 2024 Riyadh
February 2024
February 2024
BIO CEO NY, FII Miami, and a Forbes piece on quantum AI
A quieter public month but strategic. Alex attended FII Priority Summit in Miami, the BIO CEO and Investor Conference in New York, and the NIA Workshop on behavioral & social sciences in geroscience. Forbes columns: "Quantum AI: What Good Is It?", a Bryan-Johnson-as-longevity-Kardashian reflection, and a lighter "Can A Supplement Make Your Dog Live Longer?" piece.
FII Priority Summit MiamiBIO CEO & Investor Conference NYForbes: Quantum AI — What Good Is It?NIA Workshop on geroscience
January 2024
January 2024
Davos debut, Menarini's first Insilico deal, and the Forbes Asia cover
The year opened at Davos. Alex spoke at the World Economic Forum Annual Meeting, headlined the Longevity Investors Lunch, and addressed the WEF Open Forum "Turning Back the Clock." On January 4, Menarini's Stemline signed a $500M+ biobucks deal for Insilico's breast-cancer candidate — the first major Menarini partnership, setting up the 2025 encore. Forbes Asia ran a cover-style profile: "This Latvian Scientist Says His Startup is Winning the AI Drug Discovery Race." Tech Times covered Insilico's prospects against incurable disease. Alex also attended JPM 42nd Annual Healthcare Conference in San Francisco and the Future Health Summit 2024 in Dubai. Forbes columns kicked off the year with "Five AIDD Industry Predictions For 2024" and two scientific deep-dives (fat loss without exercise via TNIK knockout; Stanford's ENPP1 breast-cancer breakthrough). 43+ papers from the 2024 tranche surfaced, including the first generative-AI-designed PROTAC and the nach0 multimodal language model.
WEF Davos 2024Menarini $500M+ Insilico dealForbes Asia cover profileWEF Open Forum: Turning Back the ClockJPM 42nd Annual Healthcare ConferenceFuture Health Summit Dubai
Year in Review
2023 — The Year of Clinical Validation
Phase 1 success, the tenth ARDD meeting, and Forbes Chinese-market thesis
2023 was the year Insilico's AI-designed TNIK inhibitor moved decisively into the clinic. Alex spoke at JPM 41st Annual Healthcare Conference, the World Government Summit in Dubai, and LEAP 2023 Riyadh. He made his case for East-West longevity collaboration in Forbes' "10 Reasons Why Collaboration With China Will Help Billions Of People Worldwide Live Longer," hosted the tenth ARDD meeting in Copenhagen — publishing a 5-part Forbes series on it — and argued for the new category of "longevity biotechnology companies" (Forbes, September) that became a framework paper in Nature Biotechnology. Publications included the seminal "AI-powered therapeutic target discovery" review (Trends in Pharmacological Sciences, 364 citations), "Biomarkers of aging for the identification and evaluation of longevity interventions" in Cell (623 citations), and the PandaOmics AI-driven dual-purpose cancer/aging targets paper (Aging Cell, 46 citations). A year of framework-building, clinical validation, and industry credibility.
Phase 1 TNIK inhibitor clinical progressWEF Davos + World Government Summit Dubai10th ARDD meeting CopenhagenCell: Biomarkers of aging (623 citations)Trends in Pharm Sci: AI target discovery (364 citations)Forbes: Defining the longevity biotech company